lundi 1 juin 2020

Onco Actu du 1er juin 2020


5.5.1 ASCO (GÉNÉRAL)



ASCO 2020 Highlights for Saturday [OBR]











ASCO 2020 Highlights for Sunday [OBR]











New drugs make headway against lung, prostate, colon cancers [Medical XPress]











5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



AstraZeneca, Daiichi niche drug shows promise beyond breast cancer [Reuters]











5.5.10 ASCO (HÉMATO)



Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS [Takeda]











Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML [Takeda]











After starring at ASH last fall, Gilead’s new Forty Seven crew colors in more promising data for magrolimab at ASCO [EndPoints]











MTX-based Chemotherapy Combined with Low-Dose, Whole-Brain Radiotherapy Improves Progression-free Survival for Patients with Newly Diagnosed CNS Lymphoma [NRG Oncology]











5.5.11 ASCO (SNC]



ASCO: Ziopharm's IL-12 gene therapy boosts survival in hard-to-treat brain cancer [Fierce Biotech]











Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology [Ziopharma]











Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma [EndPoints]











5.5.15 ASCO (BIOPSIES LIQUIDES)



Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations [Genome Web]











Oncologists Make Progress Toward Showing Utility for Brain Cancer Liquid Biopsy [Genome Web]











5.5.16 ASCO (MÉDECINE DE PRÉCISION)



Pediatric Precision Oncology Study Matches 28 Percent of Patients to Targeted Therapies [Genome Web]











Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients [Genome Web]











Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer [Bayer]











TAPUR Study Shows Encouraging Results for Olaparib in BRCA-Mutated Advanced Prostate and Pancreatic Cancers [ASCO]











Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions [MD Anderson Cancer Center]











5.5.16.2 ASCO (MÉDECINE DE PRÉCISION-SEIN)



Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients [Myriad]











Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers [Genome Web]











Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions [Genome Web]











Exact Sciences Showcases Continued Progress In Cancer Diagnostics At ASCO 2020 [Exact Sciences]











5.5.16.3 ASCO (MÉDECINE DE PRÉCISION-KRAS, HRAS)



Kura flashes positive HRAS data on once-failed J&J drug [EndPoints]











Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma[Kura]











5.5.2 ASCO (SEIN)



Trastuzumab Achieves Slight Reduction in Recurrence for Women with HER2-Positive Ductal Carcinoma in Situ on NRG Oncology Trial NSABP B-43 [NRG Oncology]











5.5.3 ASCO (PROSTATE)



Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer [Astellas]











Myovant’s relugolix wins a pivotal prostate cancer showdown with an old standard — coming down to the wire on approvals [EndPoints]











Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine [Myovant]











5.5.4.1 ASCO (IMMUNOTHÉRAPIES-REIN)



Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy [Dana Farber Cancer Institute]











5.5.4.2 ASCO (IMMUNOTHÉRAPIES-COMBINAISONS)



ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data [Fierce Pharma]











ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? [Fierce Pharma]











Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer [AstraZeneca]











5.5.4.4 ASCO (IMMUNOTHÉRAPIES-POUMON)



As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug [EndPoints]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting [Allogene]











Headed to PhII: Allogene CEO David Chang completes a positive early snapshot of their off-the-shelf CAR-T pioneer [EndPoints]











Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors [MD Anderson Cancer Center]











5.5.4.6 ASCO (IMMUNOTHÉRAPIES-PEAU, MÉLANOME)



Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time [Sanofi]











5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)



Immunotherapy proves effective for the first time as a sole treatment for a subtype of metastatic colorectal cancer [VHIO]











Immunotherapy for bowel cancer could change clinical practice [University College London]











5.5.5 ASCO (GASTRO-INTESTINAL)



Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial [AstraZeneca]











Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial [AstraZeneca]











AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer [EndPoints]











Trastuzumab Combined with Trimodality Treatment Does Not Improve Outcomes for Patients with HER2-Overexpressing Esophageal Cancer on NRG Oncology Trial [NRG Oncology]











5.5.6 ASCO (PEAU-MÉLANOME)



Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery [Novartis]











5.5.7 ASCO (GYNÉCO)



Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment for Platinum-Sensitive Ovarian Cancer [NRG Oncology]











5.5.8 ASCO (POUMON)



Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial [AstraZeneca]











Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response [MD Anderson Cancer Center]











Study shows comprehensive genomic profiling identified co-occurring alterations that may cause treatment resistance in patients with METex14-altered non-small cell lung cancer [Dan Farber Cancer Insitute]











5.5.9 ASCO (AUTRES ORGANES)



Pfizer, Merck KGaA cement Bavencio bladder cancer win with OS data — while carving another niche in rare cancer [EndPoints]